The gap between trailing and forward P/E suggests the market expects earnings to recover, but the 2.48 PEG implies investors are paying a premium for growth that has been mid-single-digit. Because shareholders' equity is in deficit, P/B carries little analytical meaning and should not be used to anchor valuation. EV/EBITDA of 9.83 sits above Fresenius at 6.18, which may reflect the market's willingness to pay for DaVita's pure-play dialysis exposure, though this premium warrants monitoring against leverage risk.

Gross margin has held in a 28% to 34% band, consistent with reimbursement rates capping pricing power and labor costs absorbing incremental revenue. Net margin volatility between 4.4% and 7.9% is wider than the operating margin range, indicating that below-the-line items and non-controlling interests drive much of the per-share variation. Investors should prioritize net income attributable to DaVita over consolidated figures when judging durable earning power.

The sharp ROE rise is largely mechanical, since a shrinking equity base inflates the ratio even as invested capital returns stay low. ROIC in the low single digits, against a cost of debt that is likely material given a 12x-plus debt-to-equity profile, suggests limited economic spread on the capital employed. Returns appear to be compounding through financial engineering rather than improved asset productivity, which investors should monitor closely.

Debt-to-EBITDA has moved between 4.82 and 21.77 over the period, a range that suggests the leverage profile has become materially more demanding rather than stabilizing. Interest coverage has compressed from 4.80 in 2024Q2 to 3.39 most recently, which may indicate debt service is becoming less comfortable as rates remain elevated. Refinancing risk and the constraint this places on future repurchases warrant further investigation based on the reported debt maturity profile.